There are currently 186 clinical trials in Overland Park, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including Menorah Medical Center, University of Kansas Cancer Center-Overland Park, Saint Luke's South Hospital and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: University of Kansas Cancer Center-Overland Park, Overland Park, Kansas
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Saint Luke's South Hospital, Overland Park, Kansas
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Menorah Medical Center, Overland Park, Kansas +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Registry Study for Radiation Therapy Outcomes
NCT01255748
Recruiting
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2024
Locations: Kansas City Proton Institute, Overland Park, Kansas
Conditions: Neoplasms
Register for Updates
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
NCT05521022
Recruiting
This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Midwest Heart and Vascular, Overland Park, Kansas
Conditions: Amyloidosis; Systemic
Register for Updates
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
NCT05143424
Recruiting
The purpose of this study is to analyze drug-drug interactions of CBD on co-administered Morphine as first step in understanding CBD-opioid interactions.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/25/2024
Locations: AltaSciences, Overland Park, Kansas
Conditions: Opioid Use Disorder
Register for Updates
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
NCT05130866
Recruiting
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: Sarah Cannon Cancer Institute - HCA Midwest, Overland Park, Kansas
Conditions: Neurofibromatosis Type 2
Register for Updates
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
NCT04781192
Recruiting
The purpose of this study is to measure how effective combining Durvalumab and Regorafenib will be for participants with advance stage biliary track carcinoma who have received one line of prior treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: University of Kansas Cancer Center - Overland Park, Overland Park, Kansas
Conditions: Advanced Biliary Tract Cancer
Register for Updates
Amyloidosis Incidence in High-Risk Cardiac Device Patients
NCT06186167
Recruiting
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a n... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Midwest Heart & Vascular Specialists, Overland Park, Kansas
Conditions: Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type
Register for Updates
ELUCIDATE FFRct Study
NCT06018194
Recruiting
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Midwest Heart and Vascular Specialists, Overland Park, Kansas
Conditions: Coronary Artery Disease
Register for Updates
Role of Novel ILR in the Management of PVCs
NCT06060548
Recruiting
This prospective, observational study is a single center clinical registry of patients referred for management of symptomatic or asymptomatic Premature Ventricular Contractions (PVCs). Subjects will be followed through 12 months. The study will enroll approximately 50 patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Kansas City Heart Rhythm Institute - Roe Clinic, Overland Park, Kansas +1 locations
Conditions: PVC - Premature Ventricular Contraction, Myocarditis
Register for Updates
A Study of AT-02 in Subjects With Systemic Amyloidosis.
NCT05951049
Recruiting
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/29/2024
Locations: Midwest Heart and Vascular, Overland Park, Kansas
Conditions: Amyloidosis; Systemic
Register for Updates